ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 000C89

Treatment of motor dysfunction in Parkinson's disease: an overview

Identifieur interne : 000C89 ( PascalFrancis/Corpus ); précédent : 000C88; suivant : 000C90

Treatment of motor dysfunction in Parkinson's disease: an overview

Auteurs : Stéphane Thobois ; Florence Delamarre-Damier ; Pascal Derkinderen

Source :

Clinical neurology and neurosurgery [ 0303-8467 ] ; 2005.

RBID : Pascal:05-0254276

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Chirurgie, Traitement, Parkinson maladie, Lévodopa, Stimulant dopaminergique.

English descriptors

KwdEn :
- Dopamine agonist, Levodopa, Nervous system diseases, Parkinson disease, Surgery, Treatment.

Abstract

Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0303-8467`
A02	`01`			`@0 CNNSBV`
A03		`1`		`@0 Clin. neurol. neurosurg.`
A05				`@2 107`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Treatment of motor dysfunction in Parkinson's disease: an overview`
A11	`01`	`1`		`@1 THOBOIS (Stéphane)`
A11	`02`	`1`		`@1 DELAMARRE-DAMIER (Florence)`
A11	`03`	`1`		`@1 DERKINDEREN (Pascal)`
A14	`01`			`@1 Service de Neurologie, Hôpital Neurologique Pierre Wertheimer @2 Lyon @3 FRA @Z 1 aut.`
A14	`02`			`@1 ITG, Consulting Group @2 Paris @3 FRA @Z 2 aut.`
A14	`03`			`@1 Service de Neurologie et Centre d'investigations cliniques, CHU de Nantes, Hôpital Laennec @2 Nantes @3 FRA @Z 3 aut.`
A20				`@1 269-281`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 4348 @5 354000125421640010`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 171 ref.`
A47	`01`	`1`		`@0 05-0254276`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical neurology and neurosurgery`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.
C02	`01`	`X`		`@0 002B25J`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Chirurgie @5 02`
C03	`02`	`X`	`ENG`	`@0 Surgery @5 02`
C03	`02`	`X`	`SPA`	`@0 Cirugía @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 03`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 03`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @5 04`
C03	`05`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 05`
C03	`05`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 05`
C03	`05`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 05`
C03	`06`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 06`
C03	`06`	`X`	`ENG`	`@0 Dopamine agonist @5 06`
C03	`06`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 06`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 178`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0254276 INIST
ET :	Treatment of motor dysfunction in Parkinson's disease: an overview
AU :	THOBOIS (Stéphane); DELAMARRE-DAMIER (Florence); DERKINDEREN (Pascal)
AF :	Service de Neurologie, Hôpital Neurologique Pierre Wertheimer/Lyon/France (1 aut.); ITG, Consulting Group/Paris/France (2 aut.); Service de Neurologie et Centre d'investigations cliniques, CHU de Nantes, Hôpital Laennec/Nantes/France (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Clinical neurology and neurosurgery; ISSN 0303-8467; Coden CNNSBV; Pays-Bas; Da. 2005; Vol. 107; No. 4; Pp. 269-281; Bibl. 171 ref.
LA :	Anglais
EA :	Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.
CC :	002B25J
FD :	Système nerveux pathologie; Chirurgie; Traitement; Parkinson maladie; Lévodopa; Stimulant dopaminergique
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie
ED :	Nervous system diseases; Surgery; Treatment; Parkinson disease; Levodopa; Dopamine agonist
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Sistema nervioso patología; Cirugía; Tratamiento; Parkinson enfermedad; Levodopa; Estimulante dopaminérgico
LO :	INIST-4348.354000125421640010
ID :	05-0254276

Links to Exploration step

Pascal:05-0254276

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of motor dysfunction in Parkinson's disease: an overview</title>
<author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stéphane" last="Thobois">Stéphane Thobois</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Delamarre Damier, Florence" sort="Delamarre Damier, Florence" uniqKey="Delamarre Damier F" first="Florence" last="Delamarre-Damier">Florence Delamarre-Damier</name>
<affiliation><inist:fA14 i1="02"><s1>ITG, Consulting Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Derkinderen, Pascal" sort="Derkinderen, Pascal" uniqKey="Derkinderen P" first="Pascal" last="Derkinderen">Pascal Derkinderen</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Neurologie et Centre d'investigations cliniques, CHU de Nantes, Hôpital Laennec</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0254276</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0254276 INIST</idno>
<idno type="RBID">Pascal:05-0254276</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C89</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of motor dysfunction in Parkinson's disease: an overview</title>
<author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stéphane" last="Thobois">Stéphane Thobois</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Delamarre Damier, Florence" sort="Delamarre Damier, Florence" uniqKey="Delamarre Damier F" first="Florence" last="Delamarre-Damier">Florence Delamarre-Damier</name>
<affiliation><inist:fA14 i1="02"><s1>ITG, Consulting Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Derkinderen, Pascal" sort="Derkinderen, Pascal" uniqKey="Derkinderen P" first="Pascal" last="Derkinderen">Pascal Derkinderen</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Neurologie et Centre d'investigations cliniques, CHU de Nantes, Hôpital Laennec</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical neurology and neurosurgery</title>
<title level="j" type="abbreviated">Clin. neurol. neurosurg.</title>
<idno type="ISSN">0303-8467</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neurology and neurosurgery</title>
<title level="j" type="abbreviated">Clin. neurol. neurosurg.</title>
<idno type="ISSN">0303-8467</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonist</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Surgery</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Chirurgie</term>
<term>Traitement</term>
<term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0303-8467</s0>
</fA01>
<fA02 i1="01"><s0>CNNSBV</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neurol. neurosurg.</s0>
</fA03>
<fA05><s2>107</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Treatment of motor dysfunction in Parkinson's disease: an overview</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>THOBOIS (Stéphane)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DELAMARRE-DAMIER (Florence)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DERKINDEREN (Pascal)</s1>
</fA11>
<fA14 i1="01"><s1>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>ITG, Consulting Group</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Service de Neurologie et Centre d'investigations cliniques, CHU de Nantes, Hôpital Laennec</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>269-281</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>4348</s2>
<s5>354000125421640010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>171 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0254276</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical neurology and neurosurgery</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25J</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Surgery</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>06</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>178</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0254276 INIST</NO>
<ET>Treatment of motor dysfunction in Parkinson's disease: an overview</ET>
<AU>THOBOIS (Stéphane); DELAMARRE-DAMIER (Florence); DERKINDEREN (Pascal)</AU>
<AF>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer/Lyon/France (1 aut.); ITG, Consulting Group/Paris/France (2 aut.); Service de Neurologie et Centre d'investigations cliniques, CHU de Nantes, Hôpital Laennec/Nantes/France (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Clinical neurology and neurosurgery; ISSN 0303-8467; Coden CNNSBV; Pays-Bas; Da. 2005; Vol. 107; No. 4; Pp. 269-281; Bibl. 171 ref.</SO>
<LA>Anglais</LA>
<EA>Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.</EA>
<CC>002B25J</CC>
<FD>Système nerveux pathologie; Chirurgie; Traitement; Parkinson maladie; Lévodopa; Stimulant dopaminergique</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Surgery; Treatment; Parkinson disease; Levodopa; Dopamine agonist</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Cirugía; Tratamiento; Parkinson enfermedad; Levodopa; Estimulante dopaminérgico</SD>
<LO>INIST-4348.354000125421640010</LO>
<ID>05-0254276</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C89 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C89 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0254276
   |texte=   Treatment of motor dysfunction in Parkinson's disease: an overview
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Treatment of motor dysfunction in Parkinson's disease: an overview

Treatment of motor dysfunction in Parkinson's disease: an overview

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri